Health certificate for Blis

The Dunedin-based company has announced that the Ministry of Health has approved a Health Export and Free Sale Certificate for its Blis K12 Streptococcus salivarius lozenges.

"This certifies that Blis K12 Streptococcus salivarius lozenges are produced for human consumption according to the code of good manufacturing practice for the manufacturing and packaging of dietary supplements and contains ingredients that are freely available in New Zealand," the company says.

"This early achievement of a significant milestone, means that Blis Technologies remains ahead of schedule for the launch of its first product onto the New Zealand market, and for regulatory submissions in other markets."

The protein to be used in the lozenges is called Salivaricin B and is believed to prevent or control streptococcal throat infections.

In April Blis said it hoped to introduce the product to market within six months.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

BLIS Technologies announces a net deficit of $1,856k for the March 2013 financial year
Blis share price spike
Blis to clean up share register, buying small parcels
Blis K12 probiotic to get ruff ruff test in dogs
BLIS Technology forecasts wider 2013 loss, seeks to raise capital